Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, for traders a year or two might seem forever but it takes time to grow a business and time for the market to recongnize! For example, another favorite WNDEF was under the radar and continued to drop until a potential take-over was announced. Perhaps investing in more mature companies might fit your time horizon better?
As long as the company is making tangible steps forward, I'm quite optimistic ... who was it that said 'in the short-term the market is a voting machine, but in the long-term it is a weighing machine ... that is what is happening here, IMO.
Right now, we're under-the-radar! Best time to accumulate!
That's my bid... I have a big core position, but hoping for a few cheapies to trade once EDGAR is posted.
Excellent!!
Not complaining but wish I knew what was going on today! Are folks taking notice that product is hitting the shelves?
PLSB - up 17%. I don't know what is going on and whether to buy, hold or sell! Since the volume is good, guess I'll hold ...
In the meantime, I'm not complaining!
PLSB - up another 11% today ... no 10-bagger like some other folks but I'll take it!
(Hope the company is not being too optimistic on their supposed upcoming sales.)
Facebook is down slighly today on above-average volume ... therefore it must also be a bad long-term investment. To think of all the time Wallstreet analysts have wasted in analyzing the company fundametals when they could just look at today's chart!
Citibank is up slightly on very low-volume, so -- since the reverse is true -- it must be a great investment!
I wish I had known before this easy method of picking stocks!!
Stockman ... I think you should meet with some analysts of these companies and share your approach! I would do it myself but you deserve all the credit!
Unless you have some empirical evidence that high volume with limited share price movement is correlated with long term underperformance, this opinion seems quite contrived. Why not apply this technique to all stocks, rather than post here specifically?
That is very reasonable ...
If it's a 50 bagger, be patient that it might take some time to personally thank you. I'll need to regain mouth control from the permament grin on my face!
MC33 ... I humbly bow before you in gratitude!
It's very satisfying that we have all been collectively and patiently holding this one ... all of us have done well on many individual picks but it seems, on our favorites, we have been simply way ahead of the curve!
Thanks again Michael for bringing this one forward and to the team for all the shared DD ... I would never have found this on my own.
Yes, VRSEF not a pump-and-dump ... more like a buy-and-fly!
lol. (I have to remember that one!)
Very nice to see this well-deserved momentum! Malc timed it well yesterday!
Once these revenues are booked and published the stock is going to become more broadly appealing to other investors ... only going to get better!
I'm glad to see yesterday's action was not just a one time blip ... we have some momentum continuing today!
Nonetheless, I'm here for the long-haul so I'm not too worried about flucuations ... as long as the company keeps executing. Looking very good here!
"A release to say you got an order without any specifics?"
What details of the order were you expecting?
Perhaps they could provide the names and addresses of all the customers so we could all go see how things are going ... is that what you are expecting?
Welcome with your first post!
I see from stockhouse (where you posted the same thing) your numbers were off by $1M. Here is a useful response posted there by a_ra85:
"The post makes it sound like majority if G&A goes to Anna and TB. Biggest driver is employment costs but other s as well. Based on split for 2011 sept 9 months ended.
G&A - 1.2m
salary - 25%
travel - 10%
Professional fees - 10%
Rent - 10%
promo - 25%
office - 20%
Future f/s probably have more % via salary as they hired more during this time ; upto 4 FTE and a bunch of consultants.
re: promo costs - an IR firm usually runs 10k per month + extras, then trade shows attendance and booths, they also mentioned cite re-ddesigns .
Tb and Anna salary are posted for world to see. Judge for yourself.
Anyone who wants to question financials / numbers - please be very sure of what you post / your opinion or you will look foolish.
Read more at http://www.stockhouse.com/bullboards/messagedetail.aspx?s=VRS&t=LIST&m=32102557&l=0&pd=2&r=0#1G8jUMAkeOpCcMhL.99 "
ADXS/INO etc This article was very informative for me so thought I'd share. Although the title sounds negative, 'I'm actually more bullish after reading as it provides some very good context. Here are the conclusions I've drawn:
1. If I'm understanding correctly, the endpoint of India trial is life-expectancy which is not a 'qualitative endpoint'. Thus a successful phase 2 study is much more likely to lead to a successful phase 3.
2. I'm not sure if ADXS has unique mechanism of action... here is the wiki definition: (any thoughts??) http://en.wikipedia.org/wiki/Mechanism_of_action
3. Suppose that, just taking the average, there is a 60% chance of passing phase 3 ... I'll take a 60% chance of a multi-bagger any time! (Of course, the company could be bought out before phase 3, which raises the probability).
4. I still wish the India trials had a random placebo group... that would constitute to me a 'well-designed study' but you can't have everything!
http://seekingalpha.com/article/256697-why-phase-3-trials-fail-what-investors-need-to-know
Excellent! This year's sentiment feels different that last year so hopefully we don't see a pull back but a rational response (last year we probably would have got a temporary blip). We got some pretty good volume on the Canadian ticker!
Either way, whether it be a week or year, I'm sure this investment will one day look really really good!! Crazy we are still about 50% of past highs ... like you had mentioned earlier, sure would be nice if WNDEF could be settled while we are at these prices.
(I have only a couple posts remaining, so I'm checking out for now.)
Even then, add upcoming earnings and new films and the share price would still be undervalued!!!
That's the opportunity that know one talks about here ... the market cap is soooo low, that there is huge margin for error and stil be undervalued.
Can I prove to you that the library valuation is not $4M ... no.
Can you prove to me that the library valuation is not $30M ... no.
But based on sales, independent valuation, risk of jail time for fraud, company has not gone bankrupt after may years, shareholder meeting, value of being a Walmart distributor, no dilution, ... there certainly seems more value here than $5M!! If the worst-case scenarios are not assumed, then we are quite significantly undervalued.
(I'm running out of posts for the day, so this will be my last response for today.)
Thanks ... it is fun to untie the twisted logic that is often presented here!
That's a fair point!
I guess the fundamental question is how accurate can a library valuation be? If it is essentially a very rough guess, then -- yes -- it is not important, especially in delay of the audit.
If these 'experts' are reasonably accurate in their forecasts (and can be trusted), then I'd put a bigger % of my portfolio here and would very much appreciate knowing this detail.
Since this question cannot really be answered, both our opinions are valid!
There is certainly a tradeoff for delaying the audit so I appreciate your point they should just get things done. I'm just not going as far as to say the valuation would be irrelevant and I can see why managment would want their balance sheet fairly valued... thus I'm willing to give them some leeway.
I would think an auditor would have a lower tolerance for error.
If we are 75% certain the library is accurate and 95% certain the library is at least half the stated value, then as investors we'll do very well. The market cap is 5 million.
If an auditor is wrong 25% of the time, that could be a big issue for them!
Also, if the marketcap was $30million, then the accuracy would be more important for investors too!
If an independent expert says, based on analysis of potential future revenue streams, that the library is worth 10s of millions, I'd be pretty excited about that...
(On the other hand, if an indpendent expert says the library is essentially worthless, that would increase risk that future earnings are probably dependent upon only new titles. That would cause me pause...)
Yes, whatever the valuation, we'd get there eventually anyway, and this is holding up the audit.
Personally, I'd be willing to wait a couple months to get a genuine valuation, but holding up the audit longer would be very frustrating and I would not like the risk of not knowing for so long...
I agree! The market should/could react significantly!! I was meaning I don't think any of us had any serious doubts that this day would come ... we have better foresight than the market!!
And if the market does not react (although such phrase is often used by pumpers) this would be a true buying opportunity for huge gains. I remain very excited!
VRSEF - on the one hand this is not huge news as it's what we've expected all along. However, we are hugely undervalued so the only barrier to significant share-price appreciation is market-perception and execution risk. In this regard, achieving their first sales is a big deal!
http://www.marketwire.com/press-release/verisante-technology-inc-announces-first-sales-aura-revolutionary-medical-device-detection-tsx-venture-vrs-1751338.htm
http://finance.yahoo.com/news/iiroc-trading-halt-vrs-153400183.html
January 30, 2013 10:36 ET
Verisante Technology, Inc. Announces First Sales of Aura, a Revolutionary Medical Device for the Detection of Skin Cancer
Highly Anticipated Initial Production Run of 10 Aura Devices to Be Placed in Canada and Europe
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 30, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the Company has received purchase orders for Verisante Aura™ from the Company's exclusive distributors in Canada and Europe.
"This is a significant achievement for our Company as we take this ground-breaking technology to full commercialization," said Thomas Braun, President & CEO of Verisante. "The Company has been working very closely with our distribution partners on a strategic product launch. With manufacturing of Aura™ now underway and the full support of our distributors, 2013 is already shaping up to be a very successful year for our Company."
Verisante anticipates it will begin shipping Aura™ devices in February and will update the new Aura™ website with a list of clinics where patients can go to request an AuraScan™ when installations have been completed. Future reports of revenues and sales can be expected on a quarterly basis along with the reporting of our financial statements.
"Aura™ has the potential to revolutionize the way skin cancer is diagnosed," said Dan Webb, CEO of Clarion, exclusive Canadian distributor. "Clarion is committed to bringing this life-saving technology to medical professionals across Canada."
Dr. Barry Lycka, MD, a board-certified dermatologist and founder of the Canadian Skin Cancer Foundation, sees Aura™ becoming an integral part of the practice of any dermatologist who is diagnosing and treating skin cancer. "With the incidence of skin cancers on the rise and very few tools available to dermatologists to assist in the biopsy decision, I very much welcome a device such as Aura™," said Dr. Lycka, who practises in Edmonton (Alberta). "Clinical study results have shown that the device is fast, accurate and effective in improving patient outcomes."
In Europe, Michael Landsberg, President of Laserwelt, is excited to have the first Aura™ device available to German-speaking countries. "With the exclusive distribution rights for Aura™ in Germany, Austria and Liechtenstein, Laserwelt is ready to begin our sales and marketing efforts to the region's over 10,000 dermatologists and skin care specialists," said Landsberg. "The German market is highly scientific and sophisticated, and it can be a difficult market for new technologies to penetrate. However, with our depth of industry contacts and network of key opinion leaders in world-renowned University clinics, Laserwelt is in a unique position to bring these decisions makers together and introduce them to Aura's™ strong clinical study results, which we are confident will amount to significant sales."
And Dr. Henk-Peter Oonk, CEO of bo pharma BV is confident that Aura™ will be very well received in the Benelux region, where traditionally new technologies are adopted quickly. "Recent expansion of our exclusive distribution agreement for Aura™ to include the Nordic countries in addition to the Benelux region underlines our confidence in this product and this technology as we prepare for product launch."
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
For information about purchasing an Aura™ in Canada, contact Clarion Medical Technologies at: info@clarionmedical.com
For information about purchasing Aura™ in Germany, contact Laserwelt at: info@laserwelt.com
For information about purchasing Aura™ in Belgium, the Netherlands, Luxembourg, Sweden, Norway, Denmark, Finland or Iceland, contact bo pharma at: info@bo-pharma.com
VRSEF HALTED!
I'm not sure how to verify the status of the Canadian ticker but potentially some good news!
http://www.stockhouse.com/bullboards/messagedetail.aspx?s=VRS&t=LIST&m=32097569&l=0&pd=2&r=0
I looked at the previous Mac Report filing (some other company), and it is also not posted. I'm sure we're ok...
PBSV - $6.5 million cash ($2.8M total liab), $16M market cap, $5M net income 2012 and 60% YOY net income growth ... very good value here!
but...
"Because our business is dependent upon a small number of clients, the loss of a major client could impair our ability to operate profitably."
"We are aware of some pharmaceutical companies with operations in Puerto Rico whose patent rights may expire in the near future. The inability to obtain new patents and the expiration of active patents may reduce the need for our services and thereby impair our ability to operate profitably"
http://www.sec.gov/Archives/edgar/data/1304161/000135448813000352/pbsv_10k.htm
We are a compliance and technology transfer services consulting firm with a laboratory testing facility with headquarters in Puerto Rico, servicing the Puerto Rico, United States and Europe markets. The compliance consulting service sector in those markets consists of local compliance and validation consulting firms, United States dedicated validation and compliance consulting firms and large publicly traded and private domestic and foreign engineering and consulting firms. We provide a broad range of compliance related consulting services. We also provide microbiological testing services and chemical testing services through our laboratory testing facility (“Lab”) in Puerto Rico. We also provide information technology consulting services and technical training/seminars, which services are not currently significant to our operating results. We market our services to pharmaceutical, chemical, biotechnology and medical devices, and allied products companies in Puerto Rico, the United States and Europe. Our team includes more than 275 experienced engineering and life science professionals, and includes former quality assurance managers or directors, and experienced and trained professionals with bachelors, masters and doctorate degrees in health sciences and engineering.
We have a well-established and consistent relationship with the major pharmaceutical, biotechnology, medical device and chemical manufacturing companies in Puerto Rico and the United States, which provides us access to affiliated companies in other markets. We seek opportunities in markets that could yield profitable margins using our professional consulting force and also provide services such as those performed by our microbiological testing laboratory facility, our information technology service division, Integratek, and our technical training division, Pharma Serv Academy.
Integratek provides a variety of information technology services such as web pages and portals development, digital art design, intranets, extranets, software development including database integration, Windows and web applications development, software technical training and learning management systems, technology project management, and compliance consulting services, among others. Our Pharma Serv Academy division, through a network of leading industry professional experts in their field, which include resources of our own, provides technical seminars/training that incorporates the latest regulatory trends and standards as well as other related areas. Although these services are not currently significant to our operating results, our goal is to broaden the portfolio of services that we can provide to our customer base and also target other potential customers in other industries.
We believe the most significant factors to achieving future business growth includes our ability to: (i) continue to provide quality value-added compliance services to our clients; (ii) recruit and retain highly educated and experienced professionals; (iii) further expand our products and services to address the expanding needs of our clients; and (iv) expand our market presence in the United States, Europe and possibly other emerging pharmaceutical markets in order to respond to the international compliance needs of our clients. Our business is affected to the extent the current economic downturn affects the decision of our clients and potential clients to establish operations or to continue or expand their existing operations.
Does anyone actually listen to those guys?
(If so, please post we'd like to hear from you!)
Exactly. It's not obvious (to me) that for any (hypothetical) shareholder lawsuit, an SEC filing would be viewed differently in court versus an OTC filing.
Of course, I like the progress and am very much long. If an SEC filing eliminated all fraud risk, I'd sell my entire portfolio and dump it all into HHSE ... there is no volume today which implies everyone thinks the same way.
But perhaps, criminally, there is a difference with SEC jurisdiction?
After missing out on IRE ... I did get some NWBO @ 3.19. If I have time to research this one more, I'd probably pick up more ...
With so many of our picks doing well this year, I wonder how much co-movement is general senitment. If sentiment indeed hurt us last year and is helping us this year (which seems the case) it's actually a VERY good thing as we'll most certainly be able to outperform the market long-term. We'll see what happens but I'm quite excited for our progressive portfolio!
I think the market agrees ... with all the hoopla we have only $6,000 of HHSE trades today.
So it seems in-and-of-itself the filing does not provide additional legal benefits to shareholders. They've already been publicly producing financial documents so I guess there is no fundamental difference to an EDGAR filing in that regard ... makes sense ... thanks.
HHSE Question: does Edgar filing reduce fraud risk at all? If, so I might average down again as I could live with the library being over-valued.
That's been my concern ... why are they even considering these low-ball offers if there are other suitors?
On the other hand, we are going to get minimum $2.50 so there's really only 'upside risk'. Thus I'm happily holding!
Yes, I notice ...!
Let me guess your sentiment ... when they don't post to Edgar it's very bad, but when they do post to Edgar there is nothing positive to reconsider.
Here you go... you're very welcome!
http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=20684